The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

A different way to see psoriatic arthritis

Discover how PDE4 inhibition regulates the immune response in the body, believed to cause inflammation in psoriatic arthritis

About psoriatic arthritis1

Psoriatic arthritis is a systemic imunomediated disorder characterized by inflammation of joints, surrounding ligaments and tendons, and psoriatic skin lesions.1

Psoriatic arthritis has a significant negative impact on patient functionality, psychology, and quality of life. In one study, psoriatic arthritis was significantly associated with reduced work productivity.2-5

Many patients are diagnosed with psoriatic arthritis approximately 10 years after initial skin symptoms develop.6

Where can I find more information and support?

References:

  1. Gottlieb A et al. J Am Acad Dermatol. 2008;58:851-864.
  2. Husted JA et al. J Rheumatol. 2013;40(8):1349-1356.
  3. Tillett W et al. Rheumatology (Oxford). 2012;51(2):275-283.
  4. Lee S et al.P T. 2010;35(12):680-689.
  5. Singh JA et al. J Rheumatol. 2009;36(5):1012-1020.
  6. Winterfield LS et al. Ann Rheum Dis. 2005;64 Suppl 2:ii87-ii90.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.